|
EP1255738B1
(en)
*
|
2000-01-25 |
2012-03-07 |
Neurocrine Biosciences, Inc. |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
ES2314448T3
(es)
*
|
2003-07-07 |
2009-03-16 |
Neurocrine Biosciences, Inc. |
Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de la gonadotropina.
|
|
ATE557007T1
(de)
*
|
2003-07-07 |
2012-05-15 |
Neurocrine Biosciences Inc |
Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
|
|
EA200600188A1
(ru)
|
2003-07-07 |
2006-08-25 |
Ньюрокрайн Байосайенсиз, Инк. |
Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина
|
|
UA85871C2
(uk)
*
|
2004-03-15 |
2009-03-10 |
Такеда Фармасьютікал Компані Лімітед |
Інгібітори дипептидилпептидази
|
|
EA017029B1
(ru)
|
2007-04-06 |
2012-09-28 |
Ньюрокрайн Байосайенсиз, Инк. |
Антагонисты рецептора гонадотропин-рилизинг-фактора и способы их применения
|
|
PA8775701A1
(es)
|
2007-04-06 |
2009-04-23 |
Neurocrine Biosciences Inc |
Antagonista de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos
|
|
JP2010540534A
(ja)
|
2007-09-28 |
2010-12-24 |
イントレキソン コーポレーション |
生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
|
|
US8765948B2
(en)
|
2007-11-07 |
2014-07-01 |
Neurocrine Biosciences, Inc. |
Processes for the preparation of uracil derivatives
|
|
JP5757956B2
(ja)
*
|
2009-11-20 |
2015-08-05 |
エスケー ケミカルス シーオー．， エルティーディー．Ｓｋ Ｃｈｅｍｉｃａｌｓ Ｃｏ．， Ｌｔｄ． |
ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物
|
|
IL241595B2
(en)
|
2013-03-15 |
2025-10-01 |
Abbvie Inc |
Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
|
|
EP2881391A1
(en)
|
2013-12-05 |
2015-06-10 |
Bayer Pharma Aktiengesellschaft |
Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
|
|
EP3185881B1
(en)
|
2014-08-26 |
2022-03-09 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
WO2017221144A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of elagolix sodium and its polymorph
|
|
CA3031252A1
(en)
|
2016-07-21 |
2018-01-25 |
ObsEva S.A. |
Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
|
|
CN109789375B
(zh)
|
2016-08-23 |
2023-06-06 |
Swan水质分析仪表公司 |
用于对液体进行电去离子化的装置和方法
|
|
SI3518933T2
(sl)
|
2016-09-30 |
2025-05-30 |
Sumitomo Pharma Switzerland Gmbh |
Metode zdravljenja materničnih miom in endometrioze
|
|
WO2018060463A2
(en)
|
2016-09-30 |
2018-04-05 |
Myovant Sciences Gmbh |
Treatment of prostate cancer
|
|
AU2017336338B2
(en)
|
2016-09-30 |
2022-11-10 |
Sumitomo Pharma Switzerland Gmbh |
Methods of treating female infertility
|
|
WO2018111990A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Purdue Research Foundation |
Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
|
|
EP3388421B1
(en)
|
2017-04-13 |
2019-12-04 |
Sandoz AG |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
|
|
CA3059815C
(en)
|
2017-04-12 |
2020-10-27 |
Sandoz Ag |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist, elagolix
|
|
PT3388422T
(pt)
|
2017-04-13 |
2020-02-18 |
Sandoz Ag |
Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral
|
|
WO2018198086A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Lupin Limited |
Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
|
|
MA49256A
(fr)
|
2017-06-05 |
2021-05-26 |
ObsEva SA |
Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose
|
|
WO2018224063A2
(en)
*
|
2017-06-08 |
2018-12-13 |
Zentiva, K.S. |
Solid forms of elagolix
|
|
TW201919632A
(zh)
|
2017-08-18 |
2019-06-01 |
美商艾伯維有限公司 |
治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物
|
|
MX2020001877A
(es)
*
|
2017-08-18 |
2020-09-14 |
Abbvie Inc |
Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
|
|
WO2019036713A1
(en)
|
2017-08-18 |
2019-02-21 |
Abbvie Inc. |
SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
|
|
CN107935863A
(zh)
*
|
2017-11-30 |
2018-04-20 |
厦门海乐景生化有限公司 |
Elagolix的关键原料化合物C的合成方法
|
|
CN110938037A
(zh)
*
|
2018-09-21 |
2020-03-31 |
苏州鹏旭医药科技有限公司 |
一种依拉戈利钠盐药物中间体的制备方法
|
|
WO2019112968A1
(en)
|
2017-12-05 |
2019-06-13 |
Peng Wang |
Processes to produce elagolix
|
|
WO2019115019A1
(en)
|
2017-12-11 |
2019-06-20 |
Synthon B.V. |
Process for preparing elagolix
|
|
CN109970663B
(zh)
*
|
2017-12-27 |
2023-04-11 |
上海科胜药物研发有限公司 |
一种制备噁拉戈利中间体的方法
|
|
CN108129400B
(zh)
*
|
2017-12-29 |
2021-10-15 |
安帝康（无锡）生物科技有限公司 |
氘代噁拉戈利衍生物及其用途
|
|
BR112020021276A2
(pt)
|
2018-04-19 |
2021-01-26 |
Abbvie Inc. |
métodos de tratamento de sangramento menstrual intenso
|
|
CN110669013A
(zh)
*
|
2018-07-03 |
2020-01-10 |
江苏海悦康医药科技有限公司 |
一种噁拉戈利中间体的制备方法
|
|
CN112469417A
(zh)
*
|
2018-07-23 |
2021-03-09 |
艾伯维公司 |
恶拉戈利钠组合物和方法
|
|
CA3107597A1
(en)
*
|
2018-08-01 |
2020-02-06 |
Abbvie Inc. |
Dosing regimens for elagolix
|
|
EP3572406A1
(en)
|
2018-10-17 |
2019-11-27 |
Sandoz Ag |
Acid addition salt of elagolix and related compounds
|
|
MA54058A
(fr)
|
2018-10-29 |
2021-09-08 |
ObsEva SA |
Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
|
|
EP3876943A2
(en)
|
2018-11-07 |
2021-09-15 |
ObsEva S.A. |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
CN109293634A
(zh)
*
|
2018-12-04 |
2019-02-01 |
中国药科大学 |
恶拉戈利杂质的制备方法
|
|
CN109651171A
(zh)
*
|
2019-01-13 |
2019-04-19 |
苏州鹏旭医药科技有限公司 |
依拉戈利及其钠盐的中间体及其盐的制备方法和应用
|
|
AU2020209646A1
(en)
|
2019-01-15 |
2021-08-26 |
Lupin Inc. |
Deuterated elagolix-like compositions and methods
|
|
CN109761913A
(zh)
*
|
2019-02-16 |
2019-05-17 |
安徽华胜医药科技有限公司 |
一种有机金属钯催化合成elagolix中间体的方法
|
|
CN109810065B
(zh)
*
|
2019-02-16 |
2022-07-15 |
安徽华胜医药科技有限公司 |
一种恶拉戈利的合成方法
|
|
CN109651265A
(zh)
*
|
2019-02-16 |
2019-04-19 |
安徽诺全药业有限公司 |
一种Elagolix的制备方法
|
|
CN110041232A
(zh)
*
|
2019-04-10 |
2019-07-23 |
丽珠集团新北江制药股份有限公司 |
一种制备GnRHR药物关键中间体化合物的方法
|
|
CN109956906B
(zh)
*
|
2019-04-19 |
2021-01-29 |
奥锐特药业股份有限公司 |
一种噁拉戈利关键中间体的制备方法
|
|
WO2020240375A1
(en)
*
|
2019-05-24 |
2020-12-03 |
Dr. Reddy’S Laboratories Limited |
Improved process for the preparation of elagolix and its intermediates
|
|
CN110204498B
(zh)
*
|
2019-06-14 |
2020-11-27 |
奥锐特药业股份有限公司 |
一种高效合成噁拉戈利中间体的方法
|
|
CN110372608A
(zh)
*
|
2019-07-09 |
2019-10-25 |
丽珠集团新北江制药股份有限公司 |
一种促性腺激素释放激素拮抗剂的制备方法
|
|
ES2802815B2
(es)
*
|
2019-07-12 |
2022-03-14 |
Moehs Iberica Sl |
Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix
|
|
CN110372609B
(zh)
*
|
2019-07-25 |
2021-04-09 |
奥锐特药业股份有限公司 |
一种噁拉戈利钠盐的纯化方法
|
|
WO2021016929A1
(zh)
*
|
2019-07-31 |
2021-02-04 |
深圳仁泰医药科技有限公司 |
恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途
|
|
WO2021023877A2
(en)
|
2019-08-08 |
2021-02-11 |
ObsEva S.A. |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
AU2020325721A1
(en)
|
2019-08-08 |
2022-03-03 |
ObsEva S.A. |
GnRH antagonists for the treatment of estrogen-dependent disorders
|
|
IT202000001390A1
(it)
|
2020-01-24 |
2021-07-24 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
KR20220075340A
(ko)
|
2019-09-03 |
2022-06-08 |
옵스에파 에스에이 |
배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법
|
|
DE112020004177B4
(de)
|
2019-09-03 |
2024-10-02 |
Industriale Chimica S.R.L. |
Verfahren zur herstellung des natriumsalzes von 4-[[(1r)-2-[5-(2-fluor-3-methoxyphenyl)-3-[[2-fluor-6-(trifluormethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl]-1-phenylethyl]amino]butansäure (elagolix-natriumsalz) und zwischenstufen dieses verfahrens
|
|
IT201900015458A1
(it)
|
2019-09-03 |
2021-03-03 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
TWI755055B
(zh)
*
|
2019-09-18 |
2022-02-11 |
台灣神隆股份有限公司 |
用於製備惡拉戈利鈉及其中間體的方法
|
|
WO2021064561A1
(en)
*
|
2019-10-03 |
2021-04-08 |
Neuland Laboratories Limited |
An improved process for the preparation of elagolix sodium
|
|
CN112694445B
(zh)
*
|
2019-10-22 |
2023-07-28 |
成都倍特药业股份有限公司 |
一种噁拉戈利钠中间体的纯化方法
|
|
ES2822398B2
(es)
*
|
2019-10-30 |
2022-03-02 |
Moehs Iberica Sl |
3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix
|
|
WO2021130776A1
(en)
*
|
2019-12-27 |
2021-07-01 |
Msn Laboratories Private Limited, R&D Center |
An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts
|
|
CN113125575B
(zh)
*
|
2019-12-31 |
2023-04-18 |
济南尚博生物科技有限公司 |
一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法
|
|
CN111116490A
(zh)
*
|
2020-01-15 |
2020-05-08 |
奥锐特药业股份有限公司 |
一种噁拉戈利中间体水杨酸盐的制备与纯化方法
|
|
AU2021218895A1
(en)
|
2020-02-10 |
2022-09-15 |
ObsEva S.A. |
Biomarkers for oxytocin receptor antagonist therapy
|
|
WO2021177999A1
(en)
*
|
2020-03-05 |
2021-09-10 |
Abbvie Inc. |
Methods of administering elagolix
|
|
WO2021180862A1
(en)
|
2020-03-12 |
2021-09-16 |
Synthon B.V. |
Pharmaceutical compositions comprising elagolix sodium
|
|
CN111333548B
(zh)
*
|
2020-04-10 |
2022-04-26 |
江苏海悦康医药科技有限公司 |
1-(2-氟-6-(三氟甲基)苄基)脲的制备方法
|
|
CN113527213B
(zh)
*
|
2020-04-20 |
2023-01-03 |
上海英诺富成生物科技有限公司 |
促性激素释放激素受体拮抗剂及其用途
|
|
CN113683572A
(zh)
*
|
2020-05-18 |
2021-11-23 |
陈晓雯 |
噁拉戈利的中间体及其制备方法和应用
|
|
CN113880773A
(zh)
*
|
2020-07-02 |
2022-01-04 |
南京药石科技股份有限公司 |
一种噁拉戈利中间体的制备方法
|
|
CN112457258A
(zh)
*
|
2020-11-26 |
2021-03-09 |
诚达药业股份有限公司 |
一种噁拉戈利钠及其中间体的制备方法
|
|
EP4284374A1
(en)
|
2021-01-29 |
2023-12-06 |
Abbvie Inc. |
Methods of administrating elagolix
|
|
KR102656087B1
(ko)
|
2024-01-12 |
2024-04-09 |
주식회사 씨엠지 |
Led 소자의 에폭시 수지 코팅층 형성 방법
|